These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 18516783)

  • 1. [Intravitreal triamcinolone and bevacizumab injections for alternative treatment of nanophthalmic uveal effusion syndrome].
    Rüfer F; Varde MA; Roider J
    Klin Monbl Augenheilkd; 2008 Jun; 225(6):594-6. PubMed ID: 18516783
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease.
    Cakir M; Cekiç O; Yilmaz OF
    J AAPOS; 2009 Feb; 13(1):94-6. PubMed ID: 19101187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal injection: balancing the risks.
    Chong NV; Adewoyin T
    Eye (Lond); 2007 Mar; 21(3):313-6. PubMed ID: 17330108
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravitreal triamcinolone or bevacizumab for nonarteritic anterior ischemic optic neuropathy: do they merit further study?
    Kelman SE
    J Neuroophthalmol; 2007 Sep; 27(3):161-3. PubMed ID: 17895813
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone.
    Ekdawi NS; Bakri SJ
    Eye (Lond); 2007 Aug; 21(8):1128-30. PubMed ID: 17585312
    [No Abstract]   [Full Text] [Related]  

  • 6. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?
    Schaal S; Kaplan HJ; Tezel TH
    Ophthalmology; 2008 Dec; 115(12):2199-205. PubMed ID: 18930553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tachyphylaxis and bevacizumab.
    Avgikos KN; Horgan SE; Sivaraj RR; Hu K
    Ophthalmology; 2009 Sep; 116(9):1831-2; author reply 1832. PubMed ID: 19729101
    [No Abstract]   [Full Text] [Related]  

  • 9. Tachyphylaxis and bevacizumab.
    Ziemssen F; Neuhann IM; Voelker M
    Ophthalmology; 2009 Aug; 116(8):1591-2; author reply 1592-3. PubMed ID: 19651319
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.
    Soheilian M; Ramezani A; Bijanzadeh B; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Tabatabaei H; Peyman GA
    Retina; 2007; 27(9):1187-95. PubMed ID: 18046223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab tachyphylaxis.
    Falavarjani KG; Modarres M
    Ophthalmology; 2009 May; 116(5):1016-7; author reply 1017. PubMed ID: 19410964
    [No Abstract]   [Full Text] [Related]  

  • 12. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular oedema.
    Synek S; Vojniković B
    Coll Antropol; 2010 Apr; 34 Suppl 2():99-103. PubMed ID: 21305729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema.
    Forte R; Cennamo GL; Finelli M; Farese E; D'Amico G; Nicoletti G; de Crecchio G; Cennamo G
    Eye (Lond); 2010 Aug; 24(8):1325-30. PubMed ID: 20300127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
    Cheng KC; Wu WC; Chen KJ
    Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
    Hu YJ
    Eye (Lond); 2010 Aug; 24(8):1414; author reply 1414-5. PubMed ID: 20339391
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.
    Tao Y; Hou J; Jiang YR; Li XX; Jonas JB
    Eye (Lond); 2010 May; 24(5):810-5. PubMed ID: 19696805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
    Naser H; Koss MJ; Singh P; Koch F
    Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Exsudative AMD: Regression analysis of transpupillary thermotherapy with and without intravitreal injection of triamcinolone, bevacizumab and ranibizumab].
    Weber U
    Klin Monbl Augenheilkd; 2010 Nov; 227(11):897-904. PubMed ID: 20640976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral simultaneous intravitreal injections in the office setting.
    Bakri SJ; Risco M; Edwards AO; Pulido JS
    Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.